CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that it has named Deirdre Cunnane, J.D., as senior vice president, general counsel. Ms. Cunnane brings to Catabasis over 25 years of legal counsel experience.
“Deirdre brings to Catabasis a wealth of experience in corporate governance leadership and securities law,” said Jill C. Milne, chief executive officer of Catabasis. “In addition to her extensive legal expertise, Deirdre is an exceptional business leader and corporate strategist and we look forward to having her on the Catabasis executive management team.”
“I am honored to join Catabasis and be part of such a dynamic and growing company that is committed to making a meaningful impact for the patients and families affected by DMD and lipid disorders,” commented Ms. Cunnane.
Prior to joining Catabasis, Ms. Cunnane was at Advanced Technology Ventures (ATV), a venture capital firm, where she served as general counsel from January 2006 to October 2015. She also served as general counsel of Lightstone Ventures, a venture capital firm, from its founding in January 2012 until October 2015. As general counsel of ATV and Lightstone, Ms. Cunnane provided legal counsel in connection with structuring investment securities and complex capital restructurings from seed to later stage investments, as well as mergers and acquisitions and general corporate governance. Prior to ATV and Lightstone, Ms. Cunnane was an investment officer at BancBoston Ventures and deputy general counsel at BancBoston Capital. Ms. Cunnane started her law career with, and later became a partner in, Goodwin Procter, LLP’s Corporate Department. Ms. Cunnane is currently the supervisory attorney for the Harvard Law Entrepreneurship Project (HLEP), a position she has held since September 2014. Ms. Cunnane holds a J.D. from Boston College Law School and a B.S. in finance from the Boston College School of Management.
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company's technology and pipeline of drug candidates, please visit www.catabasis.com.